<br>        Inclusion Criteria:<br><br>          -  Willing and able to give written informed consent;<br><br>          -  Histological diagnosis of malignant melanoma;<br><br>          -  Stage IV melanoma;<br><br>          -  At least one injectable lesions > 5 mm (longest diameter) or at least 5 injectable<br>             lesions < 5 mm.<br><br>          -  Measurable disease. Note: lesions, which are designated for direct IL -2 injections,<br>             must not be considered in the evaluation of measurability;<br><br>          -  Men and women, at least 18 years of age;<br><br>          -  Patient must have demonstrated 1 of the following in response to at least 1 cycle of<br>             1 or more systemic regimens:<br><br>               1. relapse following an objective response (PR/CR);<br><br>               2. failed to demonstrate an objective response (PR/CR); or<br><br>               3. inability to tolerate treatment due to unacceptable toxicity<br><br>          -  At least 4 weeks since treatment (chemotherapy, biochemotherapy, surgery, radiation,<br>             immunotherapy, etc.) for melanoma and recovered from any clinically significant<br>             toxicity experienced during treatment;<br><br>          -  Life expectancy =3 months;<br><br>          -  ECOG performance status of 0 or 1;<br><br>          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy<br>             test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours before<br>             the start of ipilimumab;<br><br>          -  No known active or chronic infection with HIV, Hepatitis B, or Hepatitis C<br><br>          -  Required values for initial laboratory tests:<br><br>          -  Men of fathering potential must be using an adequate method of contraception to avoid<br>             conception throughout the study and for up to 26 weeks after the last dose of<br>             investigational product in such a manner that the risk of pregnancy is minimized<br><br>        Exclusion Criteria:<br><br>          -  Any other prior malignancy from which the patient has been disease-free for less than<br>             5 years, with the exception of adequately treated and cured basal or squamous cell<br>             skin cancer, superficial bladder cancer or carcinoma in situ of the cervix;<br><br>          -  Ocular melanoma; mucosal melanoma<br><br>          -  Either untreated or symptomatic central nervous system (CNS) metastases (patients<br>             with brain metastases who are identified at screening may be rescreened after the<br>             lesion(s) have been appropriately treated);<br><br>          -  Autoimmune disease: Patients with a history of inflammatory bowel disease are<br>             excluded from this study, as are patients with a history of symptomatic autoimmune<br>             disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma],<br>             systemic lupus erythematosus, autoimmune vasculitis [e.g., Wegener's<br>             Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g.,<br>             Guillain-Barre Syndrome). Patients with vitiligo may be included.<br><br>          -  Any underlying medical or psychiatric condition, which in the opinion of the<br>             investigator will make the administration of ipilimumab hazardous or obscure the<br>             interpretation of AEs, such as a condition associated with frequent diarrhea.<br><br>          -  Any non-oncology vaccine therapy used for prevention of infectious diseases (for up<br>             to 1 month before or after any dose of ipilimumab).<br><br>          -  A history of prior systemic treatment with ipilimumab, CD137 agonist, CTLA 4<br>             inhibitor, CTLA-4 agonist or IL-2 in stage IV melanoma.<br><br>          -  Concomitant or less than 4 weeks off therapy with any of the following: interferon;<br>             other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive<br>             agents; other investigation therapies; chronic use of systemic corticosteroids.<br><br>          -  Women of childbearing potential (WOCBP), defined in Section 5.3, who:<br><br>               1. are unwilling or unable to use an acceptable method of contraception to avoid<br>                  pregnancy for their entire study period and for at least 26 weeks after<br>                  cessation of study drug, or<br><br>               2. have a positive pregnancy test at baseline, or<br><br>               3. are pregnant or breastfeeding.<br><br>          -  Subjects who are compulsorily detained for treatment of either a psychiatric or<br>             physical (e.g., infectious) illness.<br>